Prot# AVX-301: A Phase 2b/3, Randomized, Double Blind, Dose Confirming Study of the Safety, Efficacy and Tolerability of Apricitabine versus Lamivudine in Treatment-Experienced HIV-1 Infected Patients with the M184V/I Mutation in Reverse Transcriptase

Project: Research project

Project Details

StatusFinished
Effective start/end date12/7/07 → 12/7/10

Funding

  • PPD Development (AVX-301)
  • Avexa Limited (AVX-301)